Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Phase 1 Completed 12 enrolled Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, skin irritation potential, and PK of PF-07038124 in Japanese healthy adult participants.

Timeline

Start: 2021-06-30
Primary completion: 2021-09-09
Completion: 2021-09-09

Publications

Ono R, Wada S, Matsuoka N, Tsunemi Y, Furihata K. Phase 1 Study of Topical Administration of Novel Phosphodiesterase-4 Inhibitor PF-07038124 in Japanese Healthy Participants. J Dermatol. 2025 Nov;52(11):1666-1673. doi: 10.1111/1346-8138.17914. Epub 2025 Aug 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IDREBORMILAST	Small molecule	0.01 %	Topical

Indications

No indication recorded.